Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. 

Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. 

Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors.

In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. 

The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). 

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

Innosuisse

Pureos Bioventures

Schroder Adveq

BioMedPartners

Bpifrance

High-Tech Grunderfonds

Jeito Capital

Kinled Holding

Morningside Venture Investments

Novo Holdings

RA Capital Management

Schroders Capital

Alentis Therapeutics

Anoat Therapeutics is a biotech company focused on developing treatments for cancer and fibrosis.

Anoat Therapeutics

Triveni Bio is a biotech company specializing in cancer treatment and fibrosis reversal.

Triveni Bio

Attovia is a biotech company dedicated to developing innovative therapies for cancer and fibrosis.

Attovia

NorthSea Therapeutics is a biopharmaceutical company focused on developing treatments for liver diseases and fibrosis.

NorthSea Therapeutics

FoRx Therapeutics is a biotech company specializing in cancer treatment and fibrosis reversal.

FoRx Therapeutics

Galectin Therapeutics is a biopharmaceutical company focused on the development of therapies for fibrotic diseases, including cancer-related fibrosis.

Galectin Therapeutics

Travere Therapeutics is a biopharmaceutical company dedicated to developing treatments for rare and serious kidney diseases, including those related to cancer treatment.

Travere Therapeutics

Jnana Therapeutics is a biotech company focused on developing small molecule therapies for neurodegenerative diseases, including those associated with cancer treatment.

Jnana Therapeutics

SciClone Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapies for cancer and infectious diseases.

SciClone Pharmaceuticals

STADA is a pharmaceutical company specializing in the development and marketing of pharmaceutical products, including those for cancer treatment.

STADA

Faes Farma is a pharmaceutical company dedicated to the development and commercialization of pharmaceutical products, including those for cancer treatment.

Faes Farma

Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including those related to cancer treatment.

Aquestive Therapeutics

Alentis Therapeutics is a biotech company focused on developing treatments for cancer and reversing fibrosis by targeting Claudin-1, a protein involved in disease signaling and tumor cell growth.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 6, 2024 7:58 AM	0538731d
public peers	general	May 6, 2024 7:58 AM	d0479cb0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:58 AM	9d470c14
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 6, 2024 7:58 AM	0de0e3a0
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 6, 2024 7:58 AM	e7167c18
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CH:ALENTIS

Alentis Therapeutics